Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: Preliminary results

European Journal of Nuclear Medicine

Volumn 26, Issue 12, 1999, Pages 1606-1609

  Stokkel, Marcel P M ^a   De Klerk, John H M ^b   Zelissen, Pierre M J ^b   Koppeschaar, Hans P F ^b   Van Rijk, Peter P ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Dual head positron emission tomography; Fluorine 18 fluorodeoxyglucose; Recurrent thyroid cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; THYROGLOBULIN; THYROTROPIN;

ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; MALE; ORAL DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY; THYROID CANCER;

ADULT; AGED; CELL DIFFERENTIATION; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; RECURRENCE; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033405775     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050501     Document Type: Article

References (14)

1. 1. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297-306.
2. 2. Reiners C, Muller SP, Farahati J, et al. SPECT and planar scintigraphy in diagnostic and follow-up of thyroid cancer. Exp Clin Endocrinol 1994; 102: 43-50.
3. 3. Iida Y, Hidaka A, Hatabu H, et al. Follow-up study of postoperative patients with thyroid cancer by thallium-201 scintigraphy and serum thyroglobulin measurement. J Nucl Med 1991; 32: 2098-2100.
4. 4. Feine U, Lietzenmayer R, Hanke JP, et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996; 37: 1468-1472.
5. 5. Sisson JC, Ackermann RJ, Meyer MA. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 1993; 77: 1090-1094.
6. 6. Grünwald F, Schomburg A, Bender H, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996; 23: 312-319.
7. 7. Dietlein M, Scheidhauer K, Voth E, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997; 24: 1342-1348.
8. 8. Uematsu H, Sadato N, Ohtsubo T, et al. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors. J Nucl Med 1998; 39: 453-459.
9. 9. Matsuno N, Minoshima S, Imazeki K, et al. Diagnostic values of F18-FDG PET in primary and metastatic thyroid cancer. J Nucl Med 1995; 36: 196P.
10. 10. Mazzaferri EL. Papillary thyroid carcinoma: factors influencing prognosis and current therapy. Semin Oncol 1987; 14: 315-332.
11. 11. Vassilopoulou-Sellin R, Schultz P, Haynie T. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer 1996; 78: 493-501.
12. 12. Nakada K, Katoh C, Kanegae K, et al. Thallium-201 scintigraphy to predict therapeutic outcome of iodine-131 therapy of metastatic thyroid carcinoma. J Nucl Med 1998; 39: 807-810.
13. 13. Pineda JD, Lee T, Ain K, et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995; 80: 1488-1492.
14. 14. Pachuki J, Burmeister LA. Evaluation and treatment of persistent thyroglobulinemia in patient with well-differentiated thyroid cancer. Eur J Endocrinol 1997; 137: 254-261.